Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Recommendation of “Moderate Buy” from Brokerages

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has been assigned a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $82.75.

RARE has been the subject of a number of research reports. Wells Fargo & Company began coverage on Ultragenyx Pharmaceutical in a research note on Monday, October 20th. They set an “overweight” rating and a $65.00 price target for the company. Morgan Stanley lowered their target price on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, July 14th. TD Cowen reduced their price objective on shares of Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. HC Wainwright reissued a “buy” rating and set a $80.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, September 9th. Finally, Wedbush reduced their target price on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating for the company in a report on Monday, July 14th.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, EVP Karah Herdman Parschauer sold 2,450 shares of the business’s stock in a transaction on Friday, September 12th. The stock was sold at an average price of $31.17, for a total transaction of $76,366.50. Following the sale, the executive vice president directly owned 73,271 shares of the company’s stock, valued at $2,283,857.07. The trade was a 3.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Howard Horn sold 7,942 shares of the company’s stock in a transaction on Monday, October 13th. The shares were sold at an average price of $31.51, for a total value of $250,252.42. Following the sale, the chief financial officer directly owned 98,227 shares of the company’s stock, valued at approximately $3,095,132.77. This represents a 7.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 10,456 shares of company stock valued at $328,486. Corporate insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC lifted its position in shares of Ultragenyx Pharmaceutical by 76.2% in the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 323 shares in the last quarter. Parallel Advisors LLC raised its stake in Ultragenyx Pharmaceutical by 1,061.9% during the 2nd quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 669 shares during the period. Assetmark Inc. lifted its holdings in shares of Ultragenyx Pharmaceutical by 1,706.7% in the third quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 1,024 shares in the last quarter. Smartleaf Asset Management LLC boosted its position in shares of Ultragenyx Pharmaceutical by 205.4% in the third quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 1,169 shares during the period. Finally, Covestor Ltd grew its holdings in shares of Ultragenyx Pharmaceutical by 26.0% during the third quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock valued at $54,000 after buying an additional 369 shares in the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Stock Down 1.0%

Shares of RARE opened at $30.63 on Wednesday. The firm has a market capitalization of $2.96 billion, a PE ratio of -5.54 and a beta of 0.30. The firm has a 50-day moving average price of $31.47 and a 200 day moving average price of $32.80. Ultragenyx Pharmaceutical has a 52-week low of $25.81 and a 52-week high of $53.04.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.58). The company had revenue of $159.93 million during the quarter, compared to analyst estimates of $167.42 million. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The company’s revenue was up 14.6% on a year-over-year basis. During the same period in the prior year, the company posted ($1.40) earnings per share. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. On average, equities analysts expect that Ultragenyx Pharmaceutical will post -5.18 EPS for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.